Operating Income (Loss) in USD of GALECTIN THERAPEUTICS INC from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
GALECTIN THERAPEUTICS INC quarterly/annual Operating Income (Loss) history and change rate from Q2 2010 to Q3 2025.
  • GALECTIN THERAPEUTICS INC Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$4.2M, a 53.7% increase year-over-year.
  • GALECTIN THERAPEUTICS INC Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$29.1M, a 26.3% increase year-over-year.
  • GALECTIN THERAPEUTICS INC annual Operating Income (Loss) for 2024 was -$42.4M, a 11.5% decline from 2023.
  • GALECTIN THERAPEUTICS INC annual Operating Income (Loss) for 2023 was -$38.1M, a 0.73% increase from 2022.
  • GALECTIN THERAPEUTICS INC annual Operating Income (Loss) for 2022 was -$38.4M, a 27.1% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

GALECTIN THERAPEUTICS INC Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$29.1M -$4.2M +$4.87M +53.7% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$34M -$4.63M +$6.67M +59% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$40.7M -$7.9M +$1.75M +18.1% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$42.4M -$12.4M -$2.87M -30% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 -$39.6M -$9.07M +$100K +1.09% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$39.7M -$11.3M -$2.29M -25.4% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$37.4M -$9.65M +$694K +6.71% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$38.1M -$9.56M +$1.07M +10.1% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 -$39.1M -$9.17M -$1.04M -12.9% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$38.1M -$9M +$659K +6.82% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 -$38.8M -$10.3M -$407K -4.1% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 -$38.4M -$10.6M -$3.21M -43.2% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024
Q3 2022 -$35.1M -$8.12M +$122K +1.48% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 -$35.3M -$9.66M -$1.47M -17.9% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$33.8M -$9.94M -$3.62M -57.3% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 -$30.2M -$7.43M +$407K +5.2% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023
Q3 2021 -$30.6M -$8.24M -$2.32M -39.1% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$28.3M -$8.19M -$2.09M -34.3% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$26.2M -$6.32M -$2.73M -76.3% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q4 2020 -$23.4M -$7.83M -$2.64M -51% 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022
Q3 2020 -$20.8M -$5.93M -$3.06M -107% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 -$17.7M -$6.1M -$3.08M -102% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021
Q1 2020 -$14.7M -$3.58M -$1.22M -51.4% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021
Q4 2019 -$13.4M -$5.19M -$2.2M -73.8% 01 Oct 2019 31 Dec 2019 10-K 31 Mar 2021
Q3 2019 -$11.2M -$2.86M -$183K -6.83% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020
Q2 2019 -$11.1M -$3.02M +$739K +19.7% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020
Q1 2019 -$11.8M -$2.37M +$1.81M +43.3% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020
Q4 2018 -$13.6M -$2.99M -$612K -25.8% 01 Oct 2018 31 Dec 2018 10-K 16 Mar 2020
Q3 2018 -$13M -$2.68M +$1.73M +39.3% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$14.7M -$3.76M +$755K +16.7% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 -$15.5M -$4.18M +$768K +15.5% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019
Q4 2017 -$16.2M -$2.37M +$2.23M +48.4% 01 Oct 2017 31 Dec 2017 10-K 06 Mar 2019
Q3 2017 -$18.5M -$4.41M +$123K +2.71% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018
Q2 2017 -$18.6M -$4.51M +$1.02M +18.4% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018
Q1 2017 -$19.6M -$4.95M +$1.87M +27.4% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018
Q4 2016 -$21.5M -$4.6M +$84K +1.79% 01 Oct 2016 31 Dec 2016 10-K 29 Mar 2018
Q3 2016 -$21.6M -$4.54M +$1.36M +23.1% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017
Q2 2016 -$22.9M -$5.53M -$874K -18.8% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017
Q1 2016 -$22.1M -$6.81M -$1.97M -40.8% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017
Q4 2015 -$20.1M -$4.68M -$949K -25.4% 01 Oct 2015 31 Dec 2015 10-K 28 Mar 2017
Q3 2015 -$19.1M -$5.9M -$2.42M -69.7% 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016
Q2 2015 -$16.7M -$4.66M -$1.28M -38% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016
Q1 2015 -$15.4M -$4.84M +$4K +0.08% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016
Q4 2014 -$15.4M -$3.73M -$930K -33.2% 01 Oct 2014 31 Dec 2014 10-K 15 Mar 2016
Q3 2014 -$14.5M -$3.48M +$68K +1.92% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015
Q2 2014 -$14.6M -$3.38M -$828K -32.5% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015
Q1 2014 -$13.7M -$4.84M -$1.64M -51% 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015
Q4 2013 -$12.1M -$2.8M -$422K -17.7% 01 Oct 2013 31 Dec 2013 10-K 15 Mar 2016
Q3 2013 -$11.7M -$3.55M -$649K -22.4% 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014
Q2 2013 -$11M -$2.55M +$121K +4.54% 30 Mar 2013 30 Jun 2013 10-Q 07 Aug 2014
Q1 2013 -$11.2M -$3.21M -$1.26M -64.3% 01 Jan 2013 31 Mar 2013 10-Q 13 May 2014
Q4 2012 -$9.9M -$2.38M +$990K +29.4% 01 Oct 2012 31 Dec 2012 10-K 18 Mar 2015
Q3 2012 -$10.9M -$2.9M -$863K -42.5% 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013
Q2 2012 -$10M -$2.67M +$323K +10.8% 29 Mar 2012 30 Jun 2012 10-Q 14 Aug 2013
Q1 2012 -$10.3M -$1.95M +$60K +2.98% 01 Jan 2012 31 Mar 2012 10-Q 10 May 2013
Q4 2011 -$10.4M -$3.37M 01 Oct 2011 31 Dec 2011 10-K 29 Mar 2013
Q3 2011 -$2.03M -$821K -67.7% 01 Jul 2011 30 Sep 2011 10-Q 09 Nov 2012
Q2 2011 -$2.99M -$1.64M -122% 01 Apr 2011 30 Jun 2011 10-Q 10 Aug 2012
Q1 2011 -$2.01M 01 Jan 2011 31 Mar 2011 10-Q 11 May 2012
Q3 2010 -$1.21M 01 Jul 2010 30 Sep 2010 10-Q 10 Nov 2011
Q2 2010 -$1.35M 01 Apr 2010 30 Jun 2010 10-Q 12 Aug 2011

GALECTIN THERAPEUTICS INC Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$42.4M -$4.36M -11.5% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 -$38.1M +$280K +0.73% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 -$38.4M -$8.17M -27.1% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024
2021 -$30.2M -$6.74M -28.7% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 -$23.4M -$10M -74.5% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022
2019 -$13.4M +$164K +1.21% 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021
2018 -$13.6M +$2.65M +16.3% 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2020
2017 -$16.2M +$5.23M +24.4% 01 Jan 2017 31 Dec 2017 10-K 06 Mar 2019
2016 -$21.5M -$1.4M -6.98% 01 Jan 2016 31 Dec 2016 10-K 29 Mar 2018
2015 -$20.1M -$4.65M -30.1% 01 Jan 2015 31 Dec 2015 10-K 28 Mar 2017
2014 -$15.4M -$3.33M -27.5% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2016
2013 -$12.1M -$2.21M -22.3% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016
2012 -$9.9M +$510K +4.9% 01 Jan 2012 31 Dec 2012 10-K 18 Mar 2015
2011 -$10.4M -$5.53M -113% 01 Jan 2011 31 Dec 2011 10-K 29 Mar 2013
2010 -$4.88M 01 Jan 2010 31 Dec 2010 10-K 30 Mar 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.